Mitochondrial protection by simvastatin against angiotensin II-mediated heart failure.

ABSTRACT:

Background and purpose

Mitochondrial dysfunction plays a role in the progression of cardiovascular diseases including heart failure. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins), which inhibit ROS synthesis, show cardioprotective effects in chronic heart failure. However, the beneficial role of statins in mitochondrial protection in heart failure remains unclear.

Experimental approach

Rats were treated with angiotensin II (1.5 mg·kg^-1 ·day^-1 ) or co-administered simvastatin (oral, 10 mg·kg^-1 ) for 14 days; and then administration was stopped for the following 14 days. Cardiac structure/function was examined by wheat germ agglutinin staining and echocardiography. Mitochondrial morphology and the numbers of lipid droplets, lyso

SUBMITTER: Hsieh CC 

PROVIDER: S-EPMC6780047 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature